GE's $8 billion Abbott deal falls over
Monday, 16 July, 2007
GE Healthcare and Abbott Laboratories have terminated their US$8.13 billion (A$9.5 billion) contract for the sale of Abbott's laboratory and point-of-care diagnostics businesses to GE.
In separate statements, the two companies said they were unable to agree on final terms and conditions of the proposed sale.
The agreement was announced in January this year and was aimed at broadening GE Healthcare's diagnostics business. It did not include Abbott's molecular diagnostics or diabetes units.
At the time, GE said Abbott's in vitro diagnostic technology would complement GE's in vivo diagnostic imaging systems business, as well as its molecular imaging, information technology and patient monitoring units.
Abbott's in vitro diagnostics and point-of-care business generated net sales of approximately $2.7 billion (A$3 billion) last year.
Local newspaper The Chicago Tribune quoted several analysts as saying the price was extravagant and "too good to be true" for Abbott.
'Longevity gene' could reverse damage from rapid aging disease
A gene found in supercentenarians, who live exceptionally long lives, could counteract the...
How a common gene mutation increases liver disease risk
Liver damage can be caused in people after exposure to high levels of acrolein, especially in...
Gene therapy slows Huntington's disease progression in trial
Patients receiving the treatment were found to experience 75% less progression of the disease...
